Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Bristol-Myers Squibb
Taiho Oncology, Inc.
Seagen Inc.
Verastem, Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Eli Lilly and Company
NeoImmuneTech
National Institutes of Health Clinical Center (CC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Essen Biotech
H. Lee Moffitt Cancer Center and Research Institute
The University of Texas Health Science Center at San Antonio
Mayo Clinic
City of Hope Medical Center
Columbia University
Takeda
Eli Lilly and Company
VM Oncology, LLC
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
City of Hope Medical Center
University of Kentucky
Merck Sharp & Dohme LLC
Maastricht University Medical Center
Mirati Therapeutics Inc.
Eli Lilly and Company
Cambridge University Hospitals NHS Foundation Trust
Bicara Therapeutics
Trishula Therapeutics, Inc.
Baylor College of Medicine
University of Glasgow
Trishula Therapeutics, Inc.
TME Pharma AG
DEKA Biosciences
OncoC4, Inc.
Redx Pharma Ltd
Intensity Therapeutics, Inc.
Merck Sharp & Dohme LLC
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Carisma Therapeutics Inc
Eli Lilly and Company
Astellas Pharma Inc
Icahn School of Medicine at Mount Sinai
NGM Biopharmaceuticals, Inc
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Second Affiliated Hospital, School of Medicine, Zhejiang University
ENB Therapeutics, Inc
Second Affiliated Hospital of Guangzhou Medical University
ADC Therapeutics S.A.
Coherus Oncology, Inc.